PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 1,333 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 1,333 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $66,783.30. Following the transaction, the vice president now directly owns 105,515 shares in the company, valued at approximately $5,286,301.50. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, January 7th, Mark Elliott Boulding sold 1,543 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $69,959.62.
• On Monday, December 2nd, Mark Elliott Boulding sold 85,600 shares of PTC Therapeutics stock. The stock was sold at an average price of $52.26, for a total transaction of $4,473,456.00.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $50.69 on Friday. PTC Therapeutics, Inc. has a 52-week low of $24.00 and a 52-week high of $54.16. The company has a 50-day simple moving average of $46.67 and a 200 day simple moving average of $41.49.

Analyst Upgrades and Downgrades

PTCT has been the topic of several research reports. Barclays upped their price objective on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 3rd. Royal Bank of Canada upped their price objective on shares of PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Tuesday. The Goldman Sachs Group upped their price objective on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a “sell” rating in a report on Wednesday, December 4th. Wells Fargo & Company increased their target price on shares of PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of PTC Therapeutics from $51.00 to $62.00 and gave the company an “overweight” rating in a report on Tuesday, November 19th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $58.85.

Institutional Trading of PTC Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp boosted its position in PTC Therapeutics by 132.2% during the fourth quarter. Mackenzie Financial Corp now owns 22,776 shares of the biopharmaceutical company’s stock worth $1,028,000 after purchasing an additional 12,967 shares during the period. Toronto Dominion Bank bought a new position in PTC Therapeutics during the fourth quarter worth about $148,363,000. GF Fund Management CO. LTD. bought a new position in PTC Therapeutics during the fourth quarter worth about $73,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in PTC Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,251 shares of the biopharmaceutical company’s stock worth $7,234,000 after purchasing an additional 26,274 shares during the period. Finally, Woodline Partners LP bought a new position in PTC Therapeutics during the fourth quarter worth about $7,037,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.